Scholarlink

<p>Small interfering RNAs (siRNAs) have emerged as versatile therapeutic agents for ulcerative colitis, and approaches to optimize their assembly, delivery, and on-demand release are therefore needed. Here, we present a method for the precise assembly and accurate dosing of two types of siRNAs on an enzyme-triggerable DNA origami nanodevice. We design a DNA duplex structure as an inflammation-responsive switch and demonstrate that the nanodevice accumulates autonomously and predominantly in the intestine and selectively exposes siRNAs through a translocated enzyme in inflammatory cells. We find that this strategy can effectively inhibit multiple pathogenic genes and pathways in inflamed cells, while remaining inert in healthy cells. We show that when administered to mice with DSS-induced colitis, the nanodevice increases survival rates up to 100% and exhibits robust therapeutic efficacy and biosafety. This study demonstrates that the nanodevice can serve as a switchable delivery platform for siRNA specifically targeted to the intestine.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Inflammation-specific DNA origami nanodevice for delivery of siRNAs to treat ulcerative colitis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月8日

查看全文
  • Tianci Zhang,
  • Ruoqing Li,
  • Zhenghao Wang,
  • Ye Zhou,
  • Yaojia Zhou,
  • Xiaoting Chen,
  • Cui Peng,
  • Yi Jiang,
  • Nanwei Tong,
  • Wei Li

摘要

Small interfering RNAs (siRNAs) have emerged as versatile therapeutic agents for ulcerative colitis, and approaches to optimize their assembly, delivery, and on-demand release are therefore needed. Here, we present a method for the precise assembly and accurate dosing of two types of siRNAs on an enzyme-triggerable DNA origami nanodevice. We design a DNA duplex structure as an inflammation-responsive switch and demonstrate that the nanodevice accumulates autonomously and predominantly in the intestine and selectively exposes siRNAs through a translocated enzyme in inflammatory cells. We find that this strategy can effectively inhibit multiple pathogenic genes and pathways in inflamed cells, while remaining inert in healthy cells. We show that when administered to mice with DSS-induced colitis, the nanodevice increases survival rates up to 100% and exhibits robust therapeutic efficacy and biosafety. This study demonstrates that the nanodevice can serve as a switchable delivery platform for siRNA specifically targeted to the intestine.